



US 20140030803A1

(19) **United States**

(12) **Patent Application Publication**  
**Hermet et al.**

(10) **Pub. No.: US 2014/0030803 A1**  
(43) **Pub. Date: Jan. 30, 2014**

(54) **DEVICE AND METHOD FOR  
CONCENTRATING AND DETECTING  
PATHOGENIC MICROBES FROM BLOOD  
PRODUCTS AND/OR THEIR DERIVATIVES**

(71) Applicant: **GeneOhm Sciences, Inc.**, Franklin  
Lakes, NJ (US)

(72) Inventors: **Jean-Pierre Hermet**, Boulogne (FR);  
**Isabelle Besson-Faure**, Aubagne (FR);  
**Sebastien Ribault**, Plan de Cuques (FR);  
**Yann Godfrin**, Lyon (FR); **Anne  
Monnot des Angles**, Saint-Remy (FR)

(21) Appl. No.: **13/915,535**

(22) Filed: **Jun. 11, 2013**

**Related U.S. Application Data**

(60) Division of application No. 10/795,873, filed on Mar.  
8, 2004, now Pat. No. 8,507,237, which is a continu-  
ation of application No. PCT/FR02/03132, filed on  
Sep. 13, 2002.

(30) **Foreign Application Priority Data**

Sep. 13, 2001 (FR) ..... 0111873

**Publication Classification**

(51) **Int. Cl.**  
**G01N 1/40** (2006.01)

(52) **U.S. Cl.**  
CPC ..... **G01N 1/4077** (2013.01)  
USPC ..... **435/309.1**

(57) **ABSTRACT**

The invention concerns a device and a method for concen-  
trating pathogenic germs potentially present in blood prod-  
ucts or derivatives and for detecting said germs comprising  
the following steps: (a) subjecting a sample of said blood  
product to a blood cell aggregating treatment, (b) eliminating  
the aggregates formed at step (a) by passing the treated  
sample over a first filter allowing through the contaminating  
germs but not the cell aggregates, (c) selectively lysing the  
residual cells of the filtrate obtained at step (b), (d) recuper-  
ating the contaminating germs by passing the lysate of step (c)  
over a second filter to detect the contaminating germs possi-  
bly trapped.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12

**DEVICE AND METHOD FOR  
CONCENTRATING AND DETECTING  
PATHOGENIC MICROBES FROM BLOOD  
PRODUCTS AND/OR THEIR DERIVATIVES**

RELATED APPLICATION

[0001] This is a continuation of International Application No. PCT/FR02/03132, with an international filing date of Sep. 13, 2002 (WO 03/025207, published Mar. 27, 2003), which is based on French Patent Application No. 01/11873, filed Sep. 13, 2002.

FIELD OF THE INVENTION

[0002] This invention relates a method for concentrating pathogenic microbes possibly present in blood products or their derivatives as well as detecting the microbes thereby concentrated to monitor the pathogenicity of the blood products.

BACKGROUND

[0003] The term "blood product" is understood to mean whole blood as well as any preparation stemming from the fractionation of whole blood, optionally comprising cellular components. The following can be cited as examples of blood products: concentrates of red cells or platelets, but also plasma or serum preparations.

[0004] Detection of contaminations of blood products and their derivatives by different pathogenic microbes such as bacteria, viruses, molds, yeasts and others, is one of the major problems facing the public health authorities at present as well as the blood transfusion industries. Detection tests exist, but they cannot be used on a routine basis at present. The principal problems presented by most of the tests for detecting such pathogenic microbes among a population or sub-population of blood cells are that most of the treatments that are supposed to selectively extract the pathogenic microbes simultaneously cause an elimination of these microbes. This elimination leads almost systematically to an underassessment of the presence of the microbes in the blood product tested and, thus, to an increase in the health care risk. It would therefore be advantageous to provide a new, rapid, sensitive method for detecting contamination of a blood product or its derivative by pathogenic microbes.

SUMMARY OF THE INVENTION

[0005] This invention relates to a method for detecting contaminating microbes possibly present in a blood product including blood cells including a) subjecting a sample of the blood product to an aggregation treatment of the blood cells, b) substantially eliminating aggregates formed in step (a) by passage of the sample over a first filter allowing passage of contaminating microbes, but not cell aggregates, c) selectively lysing residual cells of the filtrate obtained in step (b), d) recovering the contaminating microbes by passage of the lysate from step (c) over a second filter allowing passage of cellular debris, e) adding a marker agent of the contaminating microbes either during step (a) or step (c), and f) analyzing material on the second filter to detect labeled contaminating microbes possibly retained by the second filter.

[0006] This invention also relates to a device for concentrating contaminating microbes possibly present in a blood product including blood cells including a first watertight, sterile tank containing at least one blood cell aggregation

agent and, optionally, at least one agent for labeling pathogenic microbes, a second watertight, sterile tank containing at least one lysis agent for blood cells and, optionally, at least one agent for labeling pathogenic microbes, a first filter located between the first and second tanks and capable of retaining aggregates formed in the first tank, a second filter located downstream of the second tank and capable of retaining possible contaminating pathogenic microbes, and watertight, sterile connectors placed between the first tank and the first filter, between the first filter and the second tank, and between the second tank and the second filter.

BRIEF DESCRIPTION OF THE DRAWINGS

[0007] Other advantages and characteristics of the invention will become apparent from the examples below and the attached figures in which:

[0008] FIG. 1 is a graph illustrating platelet counting after having brought platelet concentrates into contact with different concentrations of thrombin;

[0009] FIG. 2 is a graph illustrating platelet counting after aggregation in the presence of ADP for two platelet samples;

[0010] FIG. 3 is a graph showing the platelet counting in the presence of CD9 antibodies (clone SN4) for four platelet samples;

[0011] FIG. 4 is a graph showing the results of platelet counting in the presence of increasing doses of antibody CD9 (clone 6B1) used in 3 mL of platelet concentrate;

[0012] FIG. 5 is a graph showing a dose response curve obtained in the presence of increasing concentrations of antibody CD9 (clone SN4);

[0013] FIG. 6 is a graph illustrating the agglutination of red cells in the presence of *Phaseolus vulgaris* lectin used at a concentration of 200 µg/ml for three samples of red cell concentrates;

[0014] FIG. 7 is a graph showing the effects of the lysis solution on the recovery of different pathogenic microbes in pure cultures;

[0015] FIG. 8 is a graph showing the effect of the lysis solution on the platelet number of two platelet samples;

[0016] FIG. 9 is a graph illustrating the effects of lysis on the erythrocyte count of two different samples of red cell concentrate;

[0017] FIG. 10 is a graph illustrating the counting of *Escherichia coli* bacteria within a platelet sample using polyethylene imine (PEI) as a permeabilization agent to increase penetration of the marker;

[0018] FIG. 11 is a graph illustrating the effect of the concentration of N-octyl β-D-glucopyranoside in the lysis solution on the pure bacteria cultures; and

[0019] FIG. 12 is a schematic perspective view illustrating a preferred embodiment of the device for concentrating pathogenic microbes according to aspects of the invention.

DETAILED DESCRIPTION

[0020] The method according to aspects of the invention is remarkable in that it is performed directly on a sample stemming from a blood product collected from a subject without prior treatment or dilution. The method for detecting pathogenic microbes comprises selectively concentrating the pathogenic microbes, then, once they have been concentrated, detecting them by techniques known in the art. Selective concentration of the pathogenic microbes is performed

by sequential or simultaneous elimination of the different populations of blood cells present in a blood product sample.

**[0021]** The method for concentrating pathogenic microbes according to aspects of the invention comprises a first step of concentrating the pathogenic microbes consisting of reducing the blood cell populations by selective aggregation of the cells, followed by a filtration step to collect in the filtrate the unaggregated, concentrated pathogenic microbes and retain on the filter the blood cell aggregates.

**[0022]** The term "aggregation", in the context of this invention, is understood to mean any action leading to the formation of cell aggregates. The term "cell aggregates" is understood to mean any group of cells comprising more than two cells and the size of which is greater than that of an isolated cell. In the context of this invention, an aggregate can be obtained either by aggregation, such as aggregation of platelets subsequent to their activation, an agglutination, such as agglutination of red cells obtained when they are in the presence of particular molecules, or bringing together cells induced by a change in the electrostatic charge of their membranes or other adhesion mechanisms or bringing together cells leading to the grouping together of more than two cells.

**[0023]** According to preferred embodiments, the aggregation of different populations of blood cells can be performed by compounds inducing platelet aggregation or compounds inducing specific agglutination of red cells. It is known, for example, that in the presence of certain compounds, the platelets have the capacity to aggregate with each other. These aggregates can be easily separated from the pathogenic microbes by filtration. The red cells also have several agglutination properties.

**[0024]** The method for concentrating pathogenic microbes according to aspects of the invention optionally comprises a second step of reducing the concentration of populations of the predominant cells in the blood, i.e., the platelets and the red cells, consisting of lysing the unaggregated cells isolated in the first aggregation step.

**[0025]** This second step of reducing the concentration of blood cell populations enables a reduction on the order of 4 log (from about  $10^9$  to about  $10^5$  cells/ml) regarding the concentration of platelets and on the order of 5 log (from about  $10^{10}$  to about  $10^5$ ) regarding the concentration of red cells.

**[0026]** More precisely, this invention provides a method for concentrating contaminating microbes possibly present in a blood product comprising blood cells, comprising the following steps:

**[0027]** a) a sample of the blood product is subjected to an aggregation treatment of the blood cells,

**[0028]** b) aggregates formed in step (a) are eliminated by passage of the treated sample over a first filter allowing passage of the contaminating microbes, but not the cell aggregates,

**[0029]** c) residual cells of the filtrate obtained in step (b) are lysed selectively,

**[0030]** d) contaminating microbes are recovered by passage of the lysate from step (c) over a second filter allowing passage of the cellular debris.

**[0031]** According to a preferred embodiment, the method comprises a supplementary step of analysis of the second filter to detect the contaminating microbes possibly retained on it. The method advantageously comprises the addition of a marker agent of the contaminating microbes either during the aggregation of step (a), or during the lysis of step (c), or directly on the second filter during the analysis step (e).

**[0032]** A marker solution comprising an esterase substrate such as ChemChrome V6 is an example of a marker agent of the pathogenic microbes detectable by the method of this invention. Thus, it is possible to use a marker solution comprising a labeled antibody or a marker of nucleic acids. The marker is preferably fluorescent or coupled to a fluorochrome or an enzyme enabling degradation of a substrate thereby made fluorescent, with the possibility that the fluorescence can be detected by an excitation laser.

**[0033]** The method also comprises addition of a permeabilization agent of the contaminating microbes which can be added to at least one of the steps, either during the aggregation of step (a), or during the lysis of step (c), or directly on the second filter during the analysis of step (e), or during several of these steps.

**[0034]** Examples of permeabilization agents of the contaminating microbes include, but are not limited to, polyethylene imine, chlorhexidine diacetate, chlorhexidine digluconate, ethylene diamine tetraacetate acid (EDTA) alone or in combination with nisin as well as detergents such as N-octyl  $\beta$ -D-glucopyranoside, SDS, Tween, triton, Brij and the like.

**[0035]** According to a preferred embodiment, the blood cells of the blood product are platelets or red cells or a mixture of these two. According to another preferred embodiment, the blood cells of the blood product are platelets and the aggregation treatment of step (a) comprises bringing the sample into contact with an aggregation composition comprising at least one of the aggregation agents selected from the group comprising: 1) a specific antibody of a platelet antigen, 2) a strong agonist of platelet activation selected from among: thrombin, TRAP (thrombin receptor activating peptide), trypsin, collagen, thromboxane A2 or ionophore A23187, and 3) a weak agonist of platelet aggregation selected from among ADP, adrenalin, arachidonic acid, Von Willebrand factor, serotonin or epinephrine.

**[0036]** The concentration of CD9 antibody specific of a platelet antigen in the aggregation composition is advantageously between about 0.5  $\mu$ g/ml and about 100  $\mu$ g/ml, preferably between about 5  $\mu$ g/ml and about 40  $\mu$ g/ml.

**[0037]** The concentration of strong agonist in the aggregation composition is advantageously between:

**[0038]** about 0.5 IU/ml and about 100 IU/ml, preferably between about 1 IU/ml and about 20 IU/ml, for a thrombin type agonist;

**[0039]** about 5  $\mu$ M and about 200  $\mu$ M, preferably between about 10 and about 100  $\mu$ M, for a TRAP type agonist;

**[0040]** about 1 nM and about 500 nM, preferably between about 10 nM and about 300 nM, for a trypsin type agonist;

**[0041]** about 0.05  $\mu$ g/ml and about 50  $\mu$ g/ml, preferably between about 1  $\mu$ g/ml and about 20  $\mu$ g/ml, for a collagen type agonist;

**[0042]** about 0.01  $\mu$ g/ml and about 5  $\mu$ g/ml, preferably between about 0.1 and about 1  $\mu$ g/ml, for a thromboxane A2 type agonist;

**[0043]** about 0.005 mg/ml and about 1 mg/ml, preferably between about 0.05 and about 0.5 mg/ml, for a PAF type agonist;

**[0044]** about 0.1  $\mu$ M and about 100  $\mu$ M, preferably between about 1  $\mu$ M and about 20  $\mu$ M, for an ionophore A23187 type agonist.

**[0045]** The concentration of weak agonist in the aggregation composition is advantageously between:

**[0046]** about 0.5  $\mu$ M and about 100  $\mu$ M, preferably between about 1  $\mu$ M and about 20  $\mu$ M, for an agonist of the ADP, adrenalin or epinephrine type;

**[0047]** about 0.001 mM and about 10 mM, preferably between about 0.01 mM and about 5 mM, for an agonist of the arachidonic acid type;

**[0048]** about 0.001 mg/ml and about 1 mg/ml, preferably between about 0.01 mg/ml and about 0.5 mg/ml, for an agonist of the Von Willebrand factor type;

**[0049]** about 0.05  $\mu$ M and about 100  $\mu$ M, preferably between about 0.01  $\mu$ M and about 50 for an agonist of the serotonin type.

**[0050]** The specific antibody of a platelet antigen is preferably selected from among: an anti-CD, CD32, anti-PTA1, CD42, anti-GpIIb/IIIa and anti-GpIV antibody.

**[0051]** According to another embodiment, the blood product comprises red cells and the aggregation treatment of step (a) comprises bringing the sample into contact with an agglutination composition comprising at least one agglutination agent selected from among the lectins, polyethylene imine, polyvinylpyrrolidone (PVP), gelatins, dextrans or polyethylene glycols (PEG). The lectins advantageously have an erythroagglutinin activity. Most preferably, the lectins are selected from among the lectins of *Phaseolus vulgaris*, *Vicia sativa*, *Vicia faba* or *Erythrina corallodendron*, *Lens culinaris*, *Phytolacca Americana* or *Triticum vulgare*. The concentration of *Phaseolus vulgaris* type lectin in the agglutination composition is advantageously between about 10  $\mu$ g/ml and about 200  $\mu$ g/ml.

**[0052]** The concentration of polyethylene imine in the agglutination composition is advantageously between about 0.1% (weight/volume) and about 40% (weight/volume). The dextrans are most preferably selected from among Dextran 70, Dextran 100, Dextran 500 and the like. The concentration of dextran in the agglutination composition is advantageously between about 0.1% (weight/volume) and about 40% (weight/volume).

**[0053]** The PEG compounds are most preferably selected from among PEG35, PEG and the like. The concentration of PEG in the agglutination composition is advantageously between about 0.05% (weight/volume) and about 40% (weight/volume). The concentration of gelatin in the agglutination composition is advantageously between about 0.5% (weight/volume) and about 40% (weight/volume).

**[0054]** The PVP compounds are most preferentially selected from among PVP-40, PVP-360 and the like. The concentration of PVP in the agglutination composition is advantageously between about 0.05% (weight/volume) and about 40% (weight/volume).

**[0055]** Lysis of the cells of step (c) is advantageously performed with a lysis solution comprising one or more detergents selected from saponin, SDS, Tween 20, Triton X100, Brij 96, Polido-canol, N-octyl  $\beta$ -D-glucopyranoside and sodium carbonate. The lysis solution is preferably constituted of a mixture of saponin, Triton X100 and Tween 20. Most preferably, the lysis solution comprises saponin at a concentration (expressed in weight/volume %) between about 0.005% and about 0.5%, of Triton X100 at a concentration (expressed in weight/volume %) between about 0.001% and about 0.5% of Tween 20 at a concentration between about 0.01% and about 1% and of N-octyl  $\beta$ -D-glucopyranoside at a concentration between about 0.1% and about 0.5%.

**[0056]** Permeabilization of the bacteria is advantageously performed with a solution comprising one or more reagents selected from chlorhexidine (digluconate, diacetate), polyethylene imine, N-octyl  $\beta$ -D-glucopyranoside, nisin alone or in combination with EDTA. The permeabilization agents are

preferably used in the case of chlorhexidine at a concentration (weight/volume) between about 0.0001% (weight/volume) and about 0.1% (weight/volume), in the case of polyethylene imine at a concentration between about 5  $\mu$ g/ml and about 120  $\mu$ g/ml, in the case of N-octyl  $\beta$ -D-glucopyranoside at a concentration between about 0.1% (weight/volume) and about 0.5% (weight/volume) and in the case of nisin between about 0.1  $\mu$ g/mL and about 0.5  $\mu$ g/mL alone or in combination with EDTA at a concentration between about 1 mM and about 10 mM.

**[0057]** The method of the invention can be used to concentrate and detect numerous contaminating microbes of blood products such as aerobic and anaerobic bacteria, molds, yeasts, live and/or dead bacterial spores. The size of the pores of the first filter is advantageously between about 2  $\mu$ m and about 20  $\mu$ m. The size of the pores of the second filter is advantageously between about 0.2  $\mu$ m and about 2  $\mu$ m.

**[0058]** Detection of the contaminating microbes of step (e) of the method of the invention is advantageously performed in an enclosed device. Most preferably, the contaminating microbes capable of being concentrated are selected from among the groups of aerobic and anaerobic bacteria, molds, yeasts and live and/or dead bacterial spores. The size of the pores of the first filter is between about 2  $\mu$ m and about 20  $\mu$ m, and the size of the pores of the second filter is between about 0.2  $\mu$ m and about 2  $\mu$ m.

**[0059]** This invention also provides a device for concentrating and labeling contaminating microbes possibly present in a blood product comprising, as shown in FIG. 12:

**[0060]** a first watertight, sterile tank (1) containing at least one blood cell aggregation agent and possibly at least one agent for labeling pathogenic microbes;

**[0061]** a second watertight, sterile tank (2) containing at least one lysis agent for blood cells and possibly at least one agent for labeling pathogenic microbes;

**[0062]** a first filter (3) placed between the first and second tanks and capable of retaining the aggregates formed in the first tank;

**[0063]** a second filter (4) placed downstream of the second tank and capable of retaining the possible contaminating pathogenic microbes; and

**[0064]** watertight, sterile connector (5) placed between the first tank (1) and the first filter (3), between the first filter (3) and the second tank (2), and between the second tank (2) and the second filter (4).

**[0065]** According to a preferred embodiment, the device comprises a watertight, sterile connector (6) to connect the bag containing the blood product to the first sterile tank (1). The watertight, sterile connection (6) connecting the bag containing the blood product to the first sterile tank is advantageously equipped with a reverse lock valve (7).

**[0066]** According to another preferred embodiment, the device comprises a sampling device to sample a determined volume of the blood product directly from a storage bag of the product into the first tank (1).

**[0067]** The first watertight, sterile tank (1) is advantageously fitted with a sample suctioning system (8). The suctioning system is preferably a piston. According to another preferred embodiment, the second filter (4) is enclosed in a membrane support composed of two parts that can be separated for removing the filter. The device is advantageously enclosed and sterile.

## EXAMPLES

## I. Concentration of Pathogenic Microbes by an Aggregation Step

## I.1 Aggregation of Platelets

## Example 1

## Aggregation with a Strong Agonist: Thrombin

[0068] Thrombin is a strong agonist of platelet aggregation. Thrombin solutions (reference T8885 Sigma) were prepared at a concentration of 100 IU/ml when used at the rate of 10 IU/test and in diluted solution form (100  $\mu$ l of thrombin mother solution with the addition of 900  $\mu$ l of PBS buffer) when used at the rate of 1 IU/test.

[0069] Platelet aggregation by the intermediary of thrombin comprised:

[0070] placing 160  $\mu$ l of platelet concentrate in a tube to which was added 20  $\mu$ l of PBS buffer and 20  $\mu$ l of thrombin;

[0071] the tubes were agitated manually for 5 minutes at ambient temperature;

[0072] 800  $\mu$ l of PBS buffer was added to the tubes;

[0073] the content of the tubes was filtered on a filter with a porosity of 11  $\mu$ m;

[0074] dilutions were created in series 1/20 to 1/10 from the filtrates;

[0075] 100 ml of each dilution of the filtrate on a CB04 membrane were filtered;

[0076] an esterase labeling was performed; and

[0077] the platelets possibly retained on the membrane were counted.

[0078] Table 1 below illustrates the results obtained and shows the number of platelet aggregates obtained in the presence of thrombin used at two different concentrations. FIG. 1 graphically illustrates these results.

TABLE 1

	Control	1 IU thrombin	10 IU thrombin
PC 6	1584	374	
	1535	490	
PC 6	2622	1358	44
	2737	1399	30

## Example 2

## Platelet Aggregation with Thrombin in the Presence of Pathogenic Microbes

[0079] The experimental studies performed to evaluate the aggregation of pathogenic microbes in the presence of thrombin comprised the following steps:

[0080] a cryobead of *E. coli* was introduced into a tube of 9 ml of tryptone soy broth and incubated at 37° C. for 18-24 hours;

[0081] 160  $\mu$ l of platelet concentrate was added to 20  $\mu$ l of the *E. coli* suspension and 20  $\mu$ l of thrombin;

[0082] the tube was agitated manually for 5 minutes at ambient temperature;

[0083] 800  $\mu$ l of PBS buffer was added;

[0084] filtration was performed through a filter of 11  $\mu$ m porosity;

[0085] dilutions in series were performed: 1/20 and 1/10 and 1/10;

[0086] filtration was performed on 100  $\mu$ l of sample on a CB04 membrane;

[0087] labeling with esterase was performed; and

[0088] detection was performed.

[0089] Table 2 below shows the aggregation of the platelet concentrates with thrombin in the presence of *E. coli*.

TABLE 2

Pathogenic microbe	Platelet preparation	Thrombin	Counting results
<i>E. coli</i>	—	—	1921
	—	—	1999
<i>E. coli</i>	PC 6	—	657
			763
<i>E. coli</i>	PC 6	1 IU	140
			167
<i>E. coli</i>	PC 6	10 IU	109
			122

[0090] A clot appeared almost instantly after addition of the thrombin.

## Example 3

## Platelet Aggregation in the Presence of a Weak Agonist: ADP

[0091] ADP (Sigma) was used at a concentration of 200  $\mu$ M in distilled water.

[0092] The experimental studies performed to evaluate platelet aggregation in the presence of ADP comprised the following steps:

[0093] 400  $\mu$ l of platelet concentrate was introduced into a tube to which was added 50  $\mu$ l of PBS buffer and 50  $\mu$ l of ADP;

[0094] the tubes were agitated manually for 5 minutes at ambient temperature;

[0095] 500  $\mu$ l of PBS buffer was added;

[0096] dilutions were performed in series of 1/20 and 1/10 and 1/10;

[0097] 100  $\mu$ l of sample was filtered on a CB04 membrane;

[0098] labeling with esterase was performed; and

[0099] detection was performed.

[0100] The results illustrated in FIG. 1 show that, in the presence of ADP, the concentration of platelets was reduced by about 50% to about 90%.

## Example 4

## Platelet Aggregation with ADP in the Presence of Pathogenic Microbes

[0101] Platelet aggregation in the presence of ADP comprised the following steps:

[0102] a cryobead of *Staphylococcus epidermidis* was introduced into a tube of 9 ml of tryptone soy broth and incubated at 37° C. for 18-24 hours;

[0103] onto 400  $\mu$ l of platelet concentrate there was added 50  $\mu$ l of the suspension of *Staph. epidermidis* and 50  $\mu$ l of ADP;

[0104] the tubes were agitated manually for 5 minutes at ambient temperature;

[0105] 500  $\mu$ l of PBS buffer was added;

[0106] filtration was performed on a filter with a porosity of 5  $\mu\text{m}$ ;

[0107] dilutions were made in series of 1/20 and 1/10 and 1/10;

[0108] 100  $\mu\text{l}$  of the sample was filtered on a CB04 membrane;

[0109] labeling with an esterase was performed; and

[0110] detection was performed.

[0111] The pathogenic microbes were seeded at a high concentration to augment a possible trapping effect. ADP was added to the platelets and the bacteria at a concentration of 10  $\mu\text{m}$ .

TABLE 3

Pathogenic microbe	Platelet preparation	Aggregation agent	Results	Concentration bacteria/ml
<i>Staphylococcus epidermidis</i>	PC 6	none	590	6.0E+07
<i>Staphylococcus epidermidis</i>	PC 6	10 $\mu\text{M}$ ADP	492	4.7E+07
<i>Staphylococcus epidermidis</i>	PC 6	ADP	441	

[0112] The results obtained, shown in Table 3 above, show that 74% of bacteria are recovered after the aggregation step.

## Example 5a

## Platelet Aggregation in the Presence of a CD9 Antibody

[0113] It is known that the CD9 antibody induces platelet activation and, consequently, their aggregation. Tests were performed with two CD9 clones, clone SN4 (Ancel, ref. 156-020, concentration 100  $\mu\text{g}/\text{ml}$ ) and clone 6B1 (Hemosystem).

[0114] The selective aggregation method implemented with these CD9 antibodies comprised the following steps:

[0115] 400  $\mu\text{l}$  of platelet concentrate was added to 50  $\mu\text{l}$  of PBS buffer and 50  $\mu\text{l}$  of CD9 antibody;

[0116] the tubes were agitated manually for 5 minutes at ambient temperature;

[0117] 500  $\mu\text{l}$  of PBS buffer was added;

[0118] filtration was performed on a filter with a porosity of 5  $\mu\text{m}$ ;

[0119] dilutions were performed in series of 1/20 and 1/10 and 1/10;

[0120] 100  $\mu\text{l}$  of sample was filtered on a CB04 membrane;

[0121] labeling was performed with an esterase; and

[0122] detection was performed.

[0123] The CD9 antibody (clone SN4) was used in the presence of platelets at a final concentration of 10  $\mu\text{g}/\text{ml}$ . FIG. 2 illustrates platelet aggregation obtained in the presence of antibody CD9 (clone SN4). A dose-response curve was established to evaluate the concentration of anti-body CD9 required for platelet aggregation.

[0124] Method:

[0125] 400  $\mu\text{l}$  of platelet concentrate placed in tubes was added to different dilutions of antibody, with final concentrations ranging from 0 to 20  $\mu\text{l}/\text{ml}$  of antibody CD9;

[0126] the tubes were agitated manually for 5 minutes at ambient temperature;

[0127] 500  $\mu\text{l}$  of PBS buffer was added;

[0128] filtration was performed on a filter with a porosity of 5  $\mu\text{m}$ ;

[0129] dilutions were performed in series: four 1/10 dilutions;

[0130] 100  $\mu\text{l}$  of sample was filtered on a CB04 membrane;

[0131] labeling was performed with an esterase; and

[0132] detection was performed.

[0133] FIGS. 3 and 5 show, respectively, the counting results for aggregated platelets in the presence of increasing doses of antibody CD9 (clone SN4) and the dose-response curve thereby obtained. Counting of the residual platelets was performed with the analyzer.

[0134] The aggregation was dose dependent. The concentration of CD9 was increased as much as possible to increase the effect of aggregation. However, a compromise was established for detecting the bacteria. It was determined that the platelet concentration could be reduced from 1 to 2 log by using a concentration of about 10  $\mu\text{g}/\text{ml}$  of antibody CD9.

## Example 5b

[0135] A dose-response curve was established to evaluate the concentration of antibody CD9 (clone 6B1) for platelet aggregation.

[0136] Method:

[0137] 3 mL of platelet concentrate placed in tubes was added to different dilutions of antibody, with final concentrations ranging from 2.5  $\mu\text{g}/\text{mL}$  to 40  $\mu\text{l}/\text{mL}$  of antibody CD9;

[0138] the tubes were agitated manually for 15 minutes at ambient temperature;

[0139] filtration was performed on a filter with a porosity of 5  $\mu\text{m}$ ; and

[0140] platelet counting was performed as described above.

[0141] Attached FIG. 4 shows the counting results for aggregated platelets in the presence of increasing doses of antibody CD9 (clone 6B1).

## Example 6

## Platelet Aggregation with the CD9 Antibody in the Presence of Bacteria

[0142] Method:

[0143] a cryobead of *Staphylococcus epidermidis* was introduced into a tube of tryptone soy broth and incubated at 37° C. for 18-24 hours;

[0144] 400  $\mu\text{l}$  of platelet concentrate placed in tubes was added to 50  $\mu\text{l}$  of the *Staphylococcus epidermidis* suspension and 50  $\mu\text{l}$  of CD9;

[0145] the tubes were agitated manually for 5 minutes at ambient temperature;

[0146] 500  $\mu\text{l}$  of PBS buffer was added;

[0147] filtration was performed on a filter with a porosity of 5  $\mu\text{m}$ ;

[0148] dilutions were performed in series: four dilutions 1/10;

[0149] filtration of 100  $\mu\text{l}$  of the sample was performed on a CB04 membrane;

[0150] labeling was performed with an esterase; and

[0151] detection was performed.

[0152] Table 4 below illustrates platelet aggregation with CD9 in the presence of bacteria.

TABLE 4

Bacteria	CD9	Result	% recovery
<i>Staph. epidermidis</i>	PC 10	—	46
<i>Staph. epidermidis</i>	PC 10	+agitation	44
<i>E. coli</i>	PC 10		43
<i>E. coli</i>	PC 10	CD9 + agitation	48
			218
			243
			166
			148

[0153] These results show that the *Staphylococcus epidermidis* bacteria were recovered in a pronounced manner. For *E. coli*, the count was reduced by 36%.

#### I.2 Agglutination of red cells

[0154] Lectins are glycoproteins of nonimmune origin that agglutinate cells and/or precipitate carbohydrate complexes. These molecules readily bond with specific carbohydrates.

[0155] Two lectins were used: *Phaseolus vulgaris* PHA-E and *Vicia sativa*.

#### Example 1

##### Agglutination of Red Cells with Lectins

[0156] *Phaseolus vulgaris* PHA-E lectin (Sigma) was used at a concentration of 2 mg/ml in PBS. *Vicia sativa* lectin (Sigma) was used at the concentration of 1 mg/ml. A quick evaluation of the two lectins revealed that there is no red cell agglutination with *Vicia sativa*. On the other hand, *Phaseolus vulgaris* induced a rapid and effective agglutination.

[0157] Method:

[0158] 400  $\mu$ l of red cells were placed in tubes to which were added 50  $\mu$ l of PBS and 50  $\mu$ l of *Phaseolus vulgaris*;

[0159] the tubes were agitated manually for 5 minutes at ambient temperature;

[0160] 500  $\mu$ l of PBS buffer was added;

[0161] filtration was performed on a filter with a porosity of 5  $\mu$ m;

[0162] dilutions were performed in series: four 1/10 dilutions;

[0163] labeling was performed with an anti-glycophorine-PE antibody; and

[0164] detection was performed.

[0165] FIG. 6 shows agglutination of the red cells obtained in the presence of *Phaseolus vulgaris*. *Phaseolus vulgaris* was used in this test at a concentration of 200  $\mu$ g/ml. We saw a reproducible decrease of two logs in the concentration of red cells in the presence of *Phaseolus vulgaris*.

#### Example 2

##### Agglutination of Red Cells in the Presence of Bacteria

[0166] The preliminary tests showed that there is no interaction between the *Phaseolus* lectin and the bacteria.

[0167] Method:

[0168] a cryobead of *E. coli* was introduced into a tube of 9 ml of tryptone soy broth and incubated at 37° C. for 18-24 hours;

[0169] 400  $\mu$ l of PBS, 50  $\mu$ l of *E. coli* (pure culture) and 50  $\mu$ l of *Phaseolus vulgaris* was mixed in the tubes;

[0170] the tubes were agitated manually for 5 minutes at ambient temperature;

[0171] 500  $\mu$ l of PBS buffer was added;

[0172] filtration was performed on a 5- $\mu$ m filter;

[0173] dilutions were performed in series: four dilutions 1/10;

[0174] filtration was performed on 100  $\mu$ l of the sample on a CB04 membrane;

[0175] labeling was performed with an esterase; and

[0176] detection was performed.

[0177] The results obtained using a *Phaseolus vulgaris* concentration of 200  $\mu$ g/ml are shown in Table 5 below.

TABLE 5

Bacteria	Red Cells	Lectin (concentration)	Count	% recovery
<i>E. coli</i>	RBC 9		662	
NCTC 9001			604	
<i>E. coli</i>	RBC 9	<i>Phaseolus</i> 200 $\mu$ g/ml	544	
NCTC 9001			579	91

[0178] These results show that 91% of the bacteria were detected after the agglutination step and that after this agglutination step, the red cell concentration was reduced by two logs while the strain *E. coli* was still recovered in a pronounced manner.

#### II. Concentration of Pathogenic Microbes by Means of a Lysis Step

[0179] We evaluated the different selective lysis techniques enabling elimination of blood cells without affecting the concentration of the bacteria possibly present in the samples to be analyzed.

[0180] Following several preliminary studies, we observed that certain bacteria were resistant in the presence of detergents such as Triton X100 and determined the concentration of detergents with which the bacteria recovery percentage is desired.

#### Example 1

##### Effect of the Formulation of the Lysis Solution on Pure Bacterial Cultures

[0181] Method:

[0182] the strains were preserved in a tube of 9 ml of tryptone soy broth and incubated at 37° C. for 18-24 hours;

[0183] dilutions in series (1/10) were performed in the PBS buffer up to 10<sup>-5</sup>;

[0184] one milliliter of the last dilution was treated with 9 ml of the lysis solution 0.01% (weight/volume) of saponin, 0.1% (weight/volume) of Tween and 0.001% (weight/volume) of Triton X 100 for 15 minutes;

[0185] 100  $\mu$ l of the sample was filtered on a CB04 membrane;

[0186] labeling was performed with an esterase; and

[0187] detection was performed.

[0188] The results of these different tests are illustrated in Table 6 below in which are expressed the different bacteria recovery percentages obtained.

TABLE 6

Strain	Control	Lysed sample	% recovery
<i>E. coli</i>	132	153	98
	145	119	
<i>Bacillus cereus</i>	465	61	11
	572	54	
<i>E. coli</i>	52	44	83
	54	44	
<i>Staph. epidermidis</i>	2952	3024	101
	3069	3020	
<i>E. aerogenes</i>	841	880	110
	802	925	
<i>Ps. aeruginosa</i>	261	82	31
	215	66	
<i>Staph. aureus</i>	105	126	125
	94	122	
<i>P. mirabilis</i>	729	1129	139
	906	1151	
<i>S. typhimurium</i>	608	820	133
	600	787	
<i>Serratia marcescens</i>	1848	1826	102
	1775	1860	
<i>C. amycolatum</i>	1103	1512	156
	1167	2035	
<i>K. pneumoniae</i>	72	79	99
	82	73	
<i>P. fluorescens</i>	4039	4873	125
	3951	5105	
<i>Streptococcus bovis</i>	3074	1848	64
	2939	1978	
<i>Y. enterocolitica</i>	10,218	9888	99
	10,321	10,526	

[0189] These results are illustrated in FIG. 7.

[0190] Most of the strains are not affected by the lysis solution. The recovery percentages are consistent with the predefined predictions, between 85 and 115%, except for *Ps. aeruginosa* and *Bacillus cereus*.

#### Example 2a

##### Effect of the Formulation of the Lysis Solution on the Bacteria Seeded in the Platelets

[0191] Two strains were adapted to the growth in the platelet concentrates to simulate a contamination.

[0192] Method:

[0193] the strains *Bacillus cereus* and *Staph. aureus* were seeded in platelets in 50-ml tubes using a concentration of  $10^6$  cells in 20 ml of platelets;

[0194] the 50-ml tubes were kept in the platelet incubator at 22° C. for several days;

[0195] one milliliter of seeded platelets was diluted with 9 ml of the lysis solution;

[0196] lysis was performed for 15 minutes at ambient temperature;

[0197] 100  $\mu$ l of the sample was filtered on a CB047 membrane;

[0198] the bacteria were labeled with a stearic substrate; and

[0199] the membrane was scanned with the analyzer.

[0200] The bacteria count results after lysis are illustrated in Table 7 below.

TABLE 7

	Control	Lysed
<i>Bacillus cereus</i>	16	14
	24	27
bacteria/ml	2.0E+06	2.1E+06
<i>Staph. aureus</i>	1966	1885
	2046	1901
bacteria/ml	2.0E+08	1.9E+08

[0201] The bacteria were seeded at an initial concentration of  $5 \cdot 10^3$  cells/ml and detected several days later at concentrations on the order of  $10^6$  to  $10^9$  cells/ml. It can be seen from these experiments that the bacteria that developed in the platelets were not affected by the lysis solution.

#### Example 2b

##### Effect of the Formulation of the Lysis Solution on the Pure Bacteria Cultures

[0202] Method:

[0203] the strains were preserved in a tube of 9 ml of tryptone soy broth and incubated at 37° C. for 18-24 hours;

[0204] after determination of the number of bacteria by esterase labeling, 3000 bacteria were inoculated in 3 mL of PBS;

[0205] the 3 mL were treated with the lysis solution (NOG 0.25% to 2%) for 20 minutes; the totality of the sample was filtered on a CB04 membrane; and

[0206] counting was performed in solid phase cytometry.

[0207] The results obtained are illustrated in FIG. 11.

#### Example 3

##### Effect of the Formulation of the Lysis Composition on the Red Cells

[0208] Method:

[0209] one milliliter of red cells was diluted in 9 ml of lysis solution or 9 ml of PBS (control);

[0210] lysis was performed for 15 minutes at ambient temperature; and

[0211] the lysed or non-lysed samples were analyzed using a cell counter.

[0212] FIG. 9 shows the results obtained on the lysed red cell preparation compared to the non-lysed red-cell preparation.

#### Example 4

##### Effect of the Formulation of the Lysis Composition on the Platelets

[0213] Reproducibility of the efficacy of the lysis solution was tested. Different platelet samples were lysed and analyzed.

[0214] Method:

[0215] one milliliter of platelets was diluted in 9 ml of lysis solution;

[0216] lysis was performed for 15 minutes at ambient temperature;

[0217] dilutions in series (1/10) were created in the PBS buffer up to  $10^{-5}$ ;

[0218] 100  $\mu$ l of the sample was filtered on a CB04 membrane;

[0219] the microorganisms were labeled with an esterase substrate; and

[0220] the membrane was scanned with the analyzer.

[0221] FIG. 8 illustrates the lysis results obtained with different platelet samples.

III. Concentration of pathogenic microbes by two aggregation and lysis steps

[0222] Preparation of the sample by concentration of the pathogenic microbes in two steps comprised:

[0223] 1) specific aggregation or agglutination of the cells of the blood product, and

[0224] 2) specific lysis of the cells of the blood product.

#### Example 1

##### Specific Separation of the Platelets

[0225] Method:

[0226] A cryobead of *E. coli* was introduced in a tube of 9 ml of tryptone soy broth and incubated at 37° C. for 18-24 hours. The first aggregation step was performed as follows:

[0227] 1 ml of platelet concentrate, 50 µl of *E. coli* (pure culture) and 100 µl of CD9 was mixed in the tubes;

[0228] the tubes were agitated manually for 5 minutes at ambient temperature.

[0229] The second lysis step was then performed:

[0230] 900 µl of lysis buffer was added to 100 µl of filtrate after aggregation;

[0231] the mixture was maintained for 15 minutes at ambient temperature;

[0232] dilutions were performed in series: four dilutions 1/10;

[0233] 100 µl of the resultant sample was filtered on a CB04 membrane;

[0234] the bacteria and platelets were labeled with an esterase substrate; and

[0235] the bacteria and platelets were counted with the analyzer.

[0236] The results obtained in performing the method for the concentration of bacteria in two steps are illustrated in Table 8 below.

TABLE 8

Bacteria	Platelet concentrate (PC)	Aggregation agent	Bacteria count	% bacterial recovery
<i>E. coli</i> NCTC 9001	PC		337	
<i>E. coli</i> NCTC 9001	PC	lysis	302	86%
<i>E. coli</i> NCTC 9001	PC	CD9	266	66%
<i>E. coli</i> NCTC 9001	PC	CD9 lysis	157	45%
<i>E. coli</i> NCTC 9001	PC		138	

#### Example 2

##### Specific Separation of the Red Cells

[0237] Method:

[0238] a cryobead of *E. coli* was introduced into a tube of 9 ml of tryptone soy broth and incubated at 37° for 18-24 hours.

[0239] The agglutination step was performed as follows:

[0240] 1 ml of red cells, 50 µl of *E. coli* (pure culture) and 125 µl of lectin was mixed in the tubes;

[0241] the tubes were agitated manually for 5 minutes at ambient temperature;

[0242] filtration was performed on a filter with a porosity of 5 µm.

[0243] The second lysis step was then performed:

[0244] 900 µl of lysis buffer was added to 100 µl of the filtrate after agglutination;

[0245] the mixture was maintained for 15 minutes at ambient temperature;

[0246] dilutions were performed in series: four dilutions 1/10;

[0247] 100 µl of the resultant sample was filtered on a CB04 membrane;

[0248] the bacteria were labeled with an esterase substrate and of the red cells with an anti-glycophorin-PE antibody; and

[0249] the bacteria and red cells were counted with the analyzer.

[0250] Table 9 below shows the results obtained with the counting of the bacteria performed after the step of agglutination of the red cells with lectin followed by the lysis step.

TABLE 9

		Bacteria counts	Bacteria recovery (%)	Red cell counts
<i>E. coli</i> NCTC 9001	Red cells 10	441		3582
<i>E. coli</i> NCTC 9001	Red cells 10 lectin lysis	261	68	161
<i>E. coli</i> NCTC 9001		348		180

[0251] The red cell concentration was reduced by 1.5 log after agglutination. 68% of the bacteria were recovered after these two steps.

#### IV. Marker Agents

##### Example 1

##### Esterase Substrate ChemChrome V6

[0252] Marker solutions can be prepared from an esterase substrate and used in the detection method of the invention according to the following protocol:

[0253] a) Preparation

[0254] 10 µl of esterase substrate ChemChrome V6 per milliliter of ChemSol B16 buffer (500 µl of marker solution per membrane); and

[0255] this solution was stored at 4° C. shielded from light for a maximum of 4 hours.

[0256] b) Use

[0257] introduce a labeling buffer into a 33-mm diameter Petri dish;

[0258] distribute 500 µl of the marker solution on the buffer; and

[0259] place the CB04 membrane on the filtration gradient. Filter 100 µl of the sample to be analyzed;

[0260] place the membrane on the buffer; and

[0261] incubate for 15 minutes at 37° C.

## Example 2

## Labeled Antibody

- [0262] Thus, a marker solution comprising a labeled antibody can be used according to the following protocol:
- [0263] collect 90  $\mu$ l of a dilution of the sample;
- [0264] add 10  $\mu$ l of the anti-glycophorin-PE antibody;
- [0265] vortex and incubate for 15 minutes at ambient temperature shielded from the light;
- [0266] add 900  $\mu$ l of PBS buffer;
- [0267] place the CB04 membrane in the filtration gradient;
- [0268] filter under vacuum 100  $\mu$ l of the solution to be analyzed; and
- [0269] analyze the membrane in the analyzer, reversing the primary and tertiary cables of the analyzer.

## Example 3

## Value of the Addition of a Bacteria Permeabilization Agent to Improve the Penetration of the Marker

- [0270] Method:
- [0271] the strains were preserved in a tube of 9 ml of tryptone soy broth and incubated at 37° C. for 18-24 hours;
- [0272] after determination of the bacteria count by esterase labeling, 3000 bacteria were inoculated in 3 mL of platelet concentrate;
- [0273] the 3 mL were treated with 1 ml of the aggregation solution (CD9: clone 6B1: 30  $\mu$ g/ml, Picogreen 1/2000, PEI 40  $\mu$ g/mL at 80  $\mu$ g/mL) for 40 minutes;
- [0274] the sample was filtered through a filter with a porosity of 5  $\mu$ m;
- [0275] the sample was incubated in the lysis solution (chlorhexidine 5·10<sup>-3</sup>%, NOG 0.5%, nisin 0.2  $\mu$ g/ml, EDTA 5 mM) for 20 minutes;
- [0276] the totality of the sample was filtered on a CB04 membrane; and
- [0277] counting was performed by means of a cytometer analyzer in solid phase.

## V. CONCLUSIONS

- [0278] The technical options for achieving the excellent conditions for the preparation of pathogenic microbes were defined by these experiments.
- [0279] With regard to the platelet concentrates, these technical options comprise:
- [0280] 1) an aggregation step with, e.g., a platelet activator antibody such as CD9;

[0281] 2) a cell lysis step with a combination of detergents such as saponin, Tween 20 and Triton X 100.

[0282] With regard to the red cell concentrates:

[0283] 1) an aggregation step with a lectin such as, e.g., *Phaseolus vulgaris*;

[0284] 2) a cell lysis step with a combination of detergents such as saponin, Tween 20 and Triton X 100.

[0285] Labeling and permeabilization of the pathogenic microbes can be performed as desired during the aggregation step, the lysis step or directly on the concentrated microbes on the last filter before analysis.

1-28. (canceled)

29. A device for concentrating contaminating microbes possibly present in a blood product comprising blood cells comprising:

a first watertight, sterile tank containing at least one blood cell aggregation agent and, optionally, at least one agent for labeling pathogenic microbes;

a second watertight, sterile tank containing at least one lysis agent for blood cells and, optionally, at least one agent for labeling pathogenic microbes;

a first filter located between the first and second tanks and capable of retaining aggregates formed in said first tank; a second filter located downstream of the second tank and capable of retaining possible contaminating pathogenic microbes; and

a watertight, sterile connector placed between the first tank and the first filter, between the first filter and the second tank, and between the second tank and the second filter.

30. The device according to claim 29, further comprising a watertight, sterile connector to connect a bag containing the blood product to the first sterile tank.

31. The device according to claim 30, wherein the watertight, sterile connection connecting the bag containing the blood product to the first sterile tank has a reverse lock valve.

32. The device according to claim 29, further comprising means for sampling a determined volume of the blood product directly from a storage bag of the product into the first tank.

33. The device according to claim 30, wherein the first sterile tank is fitted with a sample suctioning system.

34. The device according to claim 33, wherein the suctioning system is a piston.

35. The device according to claim 29, wherein the second filter is enclosed in a membrane support having two parts that can be separated for removing the filter.

36. The device according to claim 29, which is enclosed and sterile.

\* \* \* \* \*

专利名称(译)	用于从血液制品和/或其衍生物浓缩和检测病原微生物的装置和方法		
公开(公告)号	<a href="#">US20140030803A1</a>	公开(公告)日	2014-01-30
申请号	US13/915535	申请日	2013-06-11
申请(专利权)人(译)	GENEOHM科学公司.		
当前申请(专利权)人(译)	Becton狄金森输液治疗系统公司		
[标]发明人	HERMET JEAN PIERRE BESSON FAURE ISABELLE RIBAUT SEBASTIEN GODFRIN YANN MONNOT DES ANGLAS ANNE		
发明人	HERMET, JEAN-PIERRE BESSON-FAURE, ISABELLE RIBAUT, SEBASTIEN GODFRIN, YANN MONNOT DES ANGLAS, ANNE		
IPC分类号	G01N1/40 G01N33/48 C12M1/12 C12M1/34 C12N1/02 C12Q C12Q1/04 C12Q1/22 C12Q1/24 C12Q1/70 G01N1/28 G01N33/53 G01N33/554 G01N33/569 G01N33/86		
CPC分类号	G01N1/4077 G01N33/569 G01N33/86		
优先权	2001011873 2001-09-13 FR		
其他公开文献	US8822211		
外部链接	<a href="#">Espacenet</a> <a href="#">USPTO</a>		

摘要(译)

本发明涉及一种用于浓缩可能存在于血液制品或衍生物中的病原菌以及用于检测所述细菌的装置和方法，包括以下步骤：(a) 对所述血液制品的样品进行血细胞聚集处理，(b) 消除步骤(a)中形成的聚集体通过使处理过的样品通过第一过滤器，允许通过污染的细菌但不通过细胞聚集体，(c) 选择性裂解步骤(b)中获得的滤液的残余细胞，(d) 恢复通过将步骤(c)的裂解物通过第二过滤器以检测可能被捕获的污染细菌来污染细菌。




FIG. 1